Skip to Main Content

Paper Details

The polo-like kinase 1 inhibitor volasertib synergistically increases radiation efficacy in glioma stem cells.
Oncotarget
15
2018
Bcl-xL, GBM, GSC, GSC lines, GSCs, PLK1, Volasertib, cancer, glioblastoma, glioma, glioma stem cells, mouse, polo-like kinase 1, tumor, tumor cell populations, volasertib
Author NameAffiliation
Ravesanker EzhilarasanThe University of Texas MD Anderson Cancer Center
Verlene HenryThe University of Texas MD Anderson Cancer Center
Roel G W VerhaakThe University of Texas MD Anderson Cancer Center
Roel G W Verhaak
Roel G W VerhaakThe University of Texas MD Anderson Cancer Center
Roel G W VerhaakThe University of Texas MD Anderson Cancer Center
Roel G W VerhaakThe University of Texas MD Anderson Cancer Center
Roel G W Verhaak
Erik P SulmanThe University of Texas MD Anderson Cancer Center
Erik P SulmanThe University of Texas MD Anderson Cancer Center
John F de GrootThe University of Texas MD Anderson Cancer Center
  • 1 - 11

Datasets

Release 1.2